Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: Role of lipoxidation via receptor-mediated mechanisms

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 6, 2009, Pages 831-836

  Iacobini, Carla ^a   Menini, Stefano ^a   Ricci, Carlo ^a   Scipioni, Angela ^a   Sansoni, Viola ^a   Cordone, Samantha ^a   Taurino, Maurizio ^b   Serino, Matteo ^c   Marano, Giuseppe ^d   Federici, Massimo ^c   Pricci, Flavia ^e   Pugliese, Giuseppe ^a,f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Department of Drug Research and Evaluation ^*  (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Advanced lipoxidation end products; Atherosclerosis; Galectin 3; Inflammation; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; APOLIPOPROTEIN E; FATTY ACID; GALECTIN 3; LIPID; LIPOXYGENASE; OXIDIZED LOW DENSITY LIPOPROTEIN; RECEPTOR; TRANSCRIPTION FACTOR; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AUTACOID; IMMUNOGLOBULIN RECEPTOR; LGALS3 PROTEIN, MOUSE; LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA SINUS; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CELL; CELL INFILTRATION; CONTROLLED STUDY; DIET; FEMALE; INFLAMMATION; LIPID DIET; LIPID METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; MACROPHAGE; MEDIATOR; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; WILD TYPE; ANIMAL; AORTA; AORTA DISEASE; AORTITIS; ATHEROGENIC DIET; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS; OXIDATIVE STRESS; PATHOLOGY; TIME;

ANIMALS; AORTA; AORTIC DISEASES; AORTITIS; APOPTOSIS; ATHEROSCLEROSIS; CHEMOTAXIS, LEUKOCYTE; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GALECTIN 3; INFLAMMATION MEDIATORS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, SCAVENGER; SIGNAL TRANSDUCTION; TH1 CELLS; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 66349127163     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.186791     Document Type: Article

References (33)

1. Hansson GK, Robertson AK, Souderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297-329.
2. Negre-Salvayre A, Coatrieux C, Ingueneau C, Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol. 2008;153:6-20.
3. Chou MY, Hartvigsen K, Hansen LF, Fogelstrand L, Shaw PX, Boullier A, Binder CJ, Witztum JL Oxidation-specific epitopes are important targets of innate immunity. J Intern Med. 2008263:479-488.
4. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids. 2003;25:283-292.
5. Sato S, Nieminen J. Seeing strangers or announcing "danger": galectin-3 in two models of innate immunity. Glycoconj J. 2004;19:583-591.
6. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun. 2001; 280:1183-1188.
7. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008;11:91-99.
8. Tobias PS, Curtiss LK. Toll-like receptors in atherosclerosis. Biochem Soc Trans. 2007;35:1453-1455.
9. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis. 2008;196:9-21.
10. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006;26:1702-1711.
11. Dumic J, Dabelic S, Flougel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616-635.
12. Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, Frigeri L, Hsu DK, Vlassara H, Liu F-T, Di Mario U. Accelerated diabetic glomerulopathy in galectin-3/AGE-receptor-3 knockout mice. FASEB J. 2001;15:2471-2479.
13. Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, Olivieri A, Sorcini M, Di Mario U, Pesce C, Pugliese G. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury. Evidence for a protective role of galectin-3 as an AGE-receptor. FASEB J. 2004;18:1773-1775.
14. Iacobini C, Oddi G, Menini S, Amadio L, Ricci C, Barsotti P, Di Pippo C, Sorcini M, Pricci F, Pugliese F, Pugliese G. Development of agedependent glomerular lesions in galectin-3/AGE-receptor-3 knockout and wild type mice. Am J Physiol. 2005;289:F611-F621.
15. Arar C, Gaudin JC, Capron L, Legrand A. Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett. 1998;430:307-311.
16. Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol. 1998;152: 1199-1208.
17. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR. Galectin-3 is an amplifier of inflammation in athero-sclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 2008;28:433-440.
18. Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP, Liu FT. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses, Am J Pathol. 2000;156:1073-1083.
19. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 1985;57:65-73.
20. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68: 231-240.
21. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519.
22. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33-43.
23. Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apoE-knockout mice. J Clin Invest. 1998;101:1717-1725.
24. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454:470-477.
25. Cipollone F, Fazia M, Mezzetti A. Novel determinants of plaque instability. J Thromb Haemost. 2005;3:1962-1975.
26. Kavurma MM, Bhindi R, Lowe HC, Chesterman C, Khachigian LM. Vessel wall apoptosis and atherosclerotic plaque instability. J Thromb Haemost. 2005;3:465-472.
27. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol. 2008;172:247-255.
28. Maedaa N, Johnson L, Kima S, Hagamana J, Friedman M, Reddick R. Anatomical differences and atherosclerosis in apolipoprotein E-deficient mice with 129/SvEv and C57BL/6 genetic backgrounds. Atherosclerosis. 2007;195:75-82.
29. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, Kagawa S, Raz A. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 2003;63:8302-8311.
30. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature. 2001;409:733-739.
31. Sano H, Hsu DK, Apgar JR, Yu L, Sharma BB, Kuwabara I, Izui S, Liu FT. Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest. 2003;112:389-397.
32. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005;25:2255-2264.
33. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, Sethi T. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008;180: 2650-2658.